Airsculpt Technologies is expected to report Q2 2026 consensus revenue of $44.14 million and EPS of $0.02, with the current stock price of $5.01 trading significantly below the average analyst price target of $6.38.
Investors are primarily focused on the company’s same-center sales growth as a barometer for operational recovery after a challenging fiscal 2025.
The company has recently benefited from significant tailwinds related to GLP-1 weight loss medications, which management believes is driving a secondary demand cycle for body contouring and skin tightening procedures. This follows a positive turn in same-store sales performance during early 2026, making this reporting period critical to confirming a sustainable upward trend in patient volume.